The Tobacco Constituent and Biomarker Assessment Core will provide a unique resource for Projects 1-3. Investigators in this Core comprise one of the leading academic laboratories in the world for chemical analysis of tobacco constituents and related metabolites and biomarkers. The following urinary metabolites will be quantified: nicotine equivalents (the total of nicotine, cotinine, and trans-3'-hydroxycotinine and their glucuronides), total NNAL (the total of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol and its glucuronides), total NNN (the total of free and glucuronidated N-nitrosonornicotine), mercapturic acids of the volatile carcinogens 1,3-butadiene, benzene, acrolein, crotonaldehyde, and ethylene oxide, and the inflammation and oxidative damage biomarkers 11-?-hydroxy-9,15-dioxo-2,3,4,5-tetranorprostane-1,20-dioic acid (PGE- M) and 9,11,15-trihydroxyprosta-5,13-dien-1-oic acid. We will also quantify the formaldehyde-DNA adduct, /V6-hydroxymethyideoxyadenosine in leukocyte DNA, and minor tobacco alkaloids in urine. These biomarkers will provide crucial information for the research being carried out in Projects 1-3.

Public Health Relevance

Methods for achieving reduction in public health harm from use of tobacco products are critical for decreasing the human cancer toll of tobacco use. The biomarkers being quantified in this core are representative of many of the major carcinogenic and tumor enhancing constituents known to be present in tobacco products. Quantifying these biomarkers will provide an important tool for the evaluation of tobacco products to determine their potential impact on public health.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54DA031659-04
Application #
8710134
Study Section
Special Emphasis Panel (ZDA1)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
4
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
City
Pittsburgh
State
PA
Country
United States
Zip Code
Pacek, Lauren R; Vandrey, Ryan; Dermody, Sarah S et al. (2016) Evaluation of a reduced nicotine product standard: Moderating effects of and impact on cannabis use. Drug Alcohol Depend 167:228-32
Perkins, Kenneth A; Kunkle, Nicole; Karelitz, Joshua L et al. (2016) Threshold dose for discrimination of nicotine via cigarette smoking. Psychopharmacology (Berl) 233:2309-17
Smith, Tracy T; Cassidy, Rachel N; Tidey, Jennifer W et al. (2016) Impact of smoking reduced nicotine content cigarettes on sensitivity to cigarette price: Further results from a multi-site clinical trial. Addiction :
von Weymarn, Linda B; Thomson, Nicole M; Donny, Eric C et al. (2016) Quantitation of the Minor Tobacco Alkaloids Nornicotine, Anatabine, and Anabasine in Smokers' Urine by High Throughput Liquid Chromatography-Mass Spectrometry. Chem Res Toxicol 29:390-7
Nardone, Natalie; Donny, Eric C; Hatsukami, Dorothy K et al. (2016) Estimations and predictors of non-compliance in switchers to reduced nicotine content cigarettes. Addiction :
Dermody, Sarah S; Tidey, Jennifer W; Denlinger, Rachel L et al. (2016) The Impact of Smoking Very Low Nicotine Content Cigarettes on Alcohol Use. Alcohol Clin Exp Res 40:606-15
Tidey, Jennifer W (2016) A behavioral economic perspective on smoking persistence in serious mental illness. Prev Med 92:31-35
Smith, Tracy T; Rupprecht, Laura E; Cwalina, Samantha N et al. (2016) Effects of Monoamine Oxidase Inhibition on the Reinforcing Properties of Low-Dose Nicotine. Neuropsychopharmacology 41:2335-43
Guillot, Casey R; Stone, Matthew D; Geary, Bree A et al. (2015) Pharmacological, sensorimotor, and expectancy effects on tobacco withdrawal: a preliminary study. Hum Psychopharmacol 30:364-71
Tidey, Jennifer W; Miller, Mollie E (2015) Smoking cessation and reduction in people with chronic mental illness. BMJ 351:h4065

Showing the most recent 10 out of 30 publications